ERBB2 and cancer: TNF was associated with 3 pathways: “Proteoglycans in Cancer,” “Human Cytomegalovirus infection,” and “Human Papillomavirus infection.” ESR1 was included in 5 pathways, notably “Pathways in Cancer” and “Proteoglycans in Cancer.” ERBB2 was involved in 15 pathways, including “Pathways in Cancer” and “Prostate Cancer.” SRC was present in “EGFR tyrosine kinase inhibitor resistance,” “Proteoglycans in Cancer,” and seven other pathways.